The Danish Clinical Quality Program and Clinical Registries (RKKP), Aarhus, Denmark.
Department of Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark; The Danish Lung Cancer Registry (DLCR), Odense University Hospital, Odense, Denmark.
Acta Oncol. 2024 May 14;63:339-342. doi: 10.2340/1651-226X.2024.26180.
There has been marked progress against lung cancer in Denmark. To gain further insight into the different aspects of the improvement, we examined the stage-specific incidence rates, stage-specific survival and mortality rates.
We used information from the Danish Lung Cancer Registry on date of diagnosis and clinical stage to calculate age-standardised incidence rates and patient survival by sex, period and stage. Information about age-standardised lung cancer-specific mortality rates by sex and period was extracted from The Danish Health Data Authority.
Firstly, the decrease in incidence rates was due to a reduction in the rates of advanced stages. Secondly, there was a gradual increase in survival across all stages, and thirdly, the mortality rates gradually decreased over time.
The improvements in survival and mortality from lung cancer were due to decreasing incidence rates of advanced cancer and improvement in survival at all stages of the disease.
丹麦在肺癌防治方面取得了显著进展。为了更深入地了解这一改善的各个方面，我们研究了特定阶段的发病率、特定阶段的生存率和死亡率。
我们使用丹麦肺癌登记处提供的有关诊断日期和临床分期的信息，按性别、时期和分期计算了年龄标准化的发病率和患者生存率。从丹麦卫生数据局提取了按性别和时期划分的年龄标准化肺癌特异性死亡率信息。
首先，发病率的下降归因于晚期癌症发病率的降低。其次，所有阶段的生存率逐渐增加，第三，死亡率随时间逐渐下降。
肺癌的生存率和死亡率的改善归因于晚期癌症发病率的下降以及疾病各个阶段生存率的提高。
